ATE463514T1 - ANTAGONISTEN DER INTERAKTION ZWISCHEN FAKTOR VIII UND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß) - Google Patents
ANTAGONISTEN DER INTERAKTION ZWISCHEN FAKTOR VIII UND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß)Info
- Publication number
- ATE463514T1 ATE463514T1 AT03725109T AT03725109T ATE463514T1 AT E463514 T1 ATE463514 T1 AT E463514T1 AT 03725109 T AT03725109 T AT 03725109T AT 03725109 T AT03725109 T AT 03725109T AT E463514 T1 ATE463514 T1 AT E463514T1
- Authority
- AT
- Austria
- Prior art keywords
- factor viii
- lrp
- interaction
- ßlow
- proteinß
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 9
- 230000003993 interaction Effects 0.000 title abstract 4
- 102000011965 Lipoprotein Receptors Human genes 0.000 title 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 102000001690 Factor VIII Human genes 0.000 abstract 8
- 108010054218 Factor VIII Proteins 0.000 abstract 8
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 abstract 3
- 239000013060 biological fluid Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 2
- 208000015294 blood coagulation disease Diseases 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37635102P | 2002-04-29 | 2002-04-29 | |
| PCT/EP2003/004425 WO2003093313A2 (en) | 2002-04-29 | 2003-04-28 | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE463514T1 true ATE463514T1 (de) | 2010-04-15 |
Family
ID=29401334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03725109T ATE463514T1 (de) | 2002-04-29 | 2003-04-28 | ANTAGONISTEN DER INTERAKTION ZWISCHEN FAKTOR VIII UND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8586538B2 (de) |
| EP (1) | EP1497330B1 (de) |
| JP (2) | JP2005535588A (de) |
| AT (1) | ATE463514T1 (de) |
| AU (1) | AU2003227687B2 (de) |
| CA (1) | CA2484155C (de) |
| DE (1) | DE60332011D1 (de) |
| DK (1) | DK1497330T3 (de) |
| ES (1) | ES2343681T3 (de) |
| WO (1) | WO2003093313A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003256299A1 (en) | 2002-07-01 | 2004-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| EP1454632A1 (de) * | 2003-02-07 | 2004-09-08 | Aventis Behring GmbH, Intellectual Property/Legal | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörungen enthaltend Peptide von Faktor VIII |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2006003183A1 (de) * | 2004-07-02 | 2006-01-12 | Alois Jungbauer | Peptide zur blockierung von fviii-inhibitoren |
| EP1816201A1 (de) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät |
| JP2009274958A (ja) | 2006-08-31 | 2009-11-26 | Nara Prefecture | 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体 |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| US20110286988A1 (en) * | 2008-06-04 | 2011-11-24 | Bayer Healthcare Llc | FVIII Muteins for Treatment of Von Willebrand Disease |
| EP2865760B1 (de) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Faktor viii, von-willebrand-faktor oder komplexe davon mit verlängerter in-vivo-halbwertzeit |
| JP5394864B2 (ja) * | 2009-09-10 | 2014-01-22 | アスモ株式会社 | モータ |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
| US9321827B2 (en) | 2010-09-15 | 2016-04-26 | Novo Nordisk A/S | Factor VIII variants having a decreased cellular uptake |
| DK2814502T3 (en) | 2012-02-15 | 2017-12-18 | Csl Behring Gmbh | Von Willebrand Factor variants with improved Factor VIII binding affinity |
| EP2796145B1 (de) | 2013-04-22 | 2017-11-01 | CSL Ltd. | Ein kovalenter komplex bestehend aus von willebrand und faktor viii verbunden mit einer disulfidbrücke |
| ES2844232T3 (es) | 2014-07-02 | 2021-07-21 | CSL Behring Lengnau AG | Factor de Von Willebrand modificado |
| CA2978374A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| SG10201910900WA (en) | 2015-05-22 | 2020-01-30 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
| MX2017014503A (es) | 2015-05-22 | 2018-08-01 | CSL Behring Lengnau AG | Polipeptidos de factor de von willebrand truncado para tratar hemofilia. |
| DK3400238T3 (da) | 2016-01-07 | 2021-07-26 | CSL Behring Lengnau AG | Muteret von willebrand faktor |
| JP6851381B6 (ja) | 2016-01-07 | 2021-04-21 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 変異切断型フォンウィルブランド因子 |
| SG10201912360SA (en) | 2016-11-11 | 2020-02-27 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| KR20190073576A (ko) | 2016-11-11 | 2019-06-26 | 체에스엘 베링 렝나우 아게 | 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU713303B2 (en) * | 1995-06-12 | 1999-11-25 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Factor IX binding peptides, derived from factor VIII and their use as inhibitors of blood coagulation |
| EP1095143B1 (de) * | 1998-05-08 | 2008-08-20 | Stichting Sanquin Bloedvoorziening | Hemmstoff zur diagnose und behandlung von haemophilia a patienten |
| EP1129186B2 (de) * | 1998-11-10 | 2016-11-30 | Stichting Sanquin Bloedvoorziening | Ein faktor viii-polypeptid mit faktor viii:c-aktivität |
| AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
-
2003
- 2003-04-28 AT AT03725109T patent/ATE463514T1/de active
- 2003-04-28 AU AU2003227687A patent/AU2003227687B2/en not_active Ceased
- 2003-04-28 US US10/512,907 patent/US8586538B2/en active Active
- 2003-04-28 EP EP03725109A patent/EP1497330B1/de not_active Expired - Lifetime
- 2003-04-28 DE DE60332011T patent/DE60332011D1/de not_active Expired - Lifetime
- 2003-04-28 ES ES03725109T patent/ES2343681T3/es not_active Expired - Lifetime
- 2003-04-28 WO PCT/EP2003/004425 patent/WO2003093313A2/en not_active Ceased
- 2003-04-28 JP JP2004501452A patent/JP2005535588A/ja active Pending
- 2003-04-28 CA CA2484155A patent/CA2484155C/en not_active Expired - Lifetime
- 2003-04-28 DK DK03725109.7T patent/DK1497330T3/da active
-
2010
- 2010-06-07 JP JP2010130425A patent/JP2010202664A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003093313A3 (en) | 2004-07-29 |
| JP2010202664A (ja) | 2010-09-16 |
| EP1497330A2 (de) | 2005-01-19 |
| AU2003227687B2 (en) | 2009-10-15 |
| JP2005535588A (ja) | 2005-11-24 |
| US8586538B2 (en) | 2013-11-19 |
| AU2003227687A1 (en) | 2003-11-17 |
| US20080219983A1 (en) | 2008-09-11 |
| WO2003093313A2 (en) | 2003-11-13 |
| CA2484155C (en) | 2015-10-13 |
| DE60332011D1 (de) | 2010-05-20 |
| ES2343681T3 (es) | 2010-08-06 |
| DK1497330T3 (da) | 2010-06-14 |
| CA2484155A1 (en) | 2003-11-13 |
| EP1497330B1 (de) | 2010-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE463514T1 (de) | ANTAGONISTEN DER INTERAKTION ZWISCHEN FAKTOR VIII UND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß) | |
| ATE349446T1 (de) | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel | |
| EA200500782A1 (ru) | Лечение геморрагического шока | |
| ATE506375T1 (de) | Gegen das c5-komponent des komplementsystems gerichtete antikörper und deren verwendung | |
| EP1638950A4 (de) | Cyclohexylglycinderivate als dipeptidylpeptidaseinhibitoren zur behandlung bzw. prevention von diabetes | |
| CY1107383T1 (el) | Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος | |
| UA86344C2 (ru) | Способ лечения сосудистых заболеваний | |
| ATE548354T1 (de) | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen | |
| ATE454140T1 (de) | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität | |
| ATE551060T1 (de) | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen | |
| NO20045056L (no) | Fremgangsmater for behandling av hepatitt | |
| ATE318601T1 (de) | Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten | |
| MA31941B1 (fr) | Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine | |
| EA201290278A1 (ru) | Способ лечения сердечной недостаточности с использованием стресскопинподобных пептидов | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| ATE466595T1 (de) | Verbindungen und methoden für das downregulating der effekte von tgf-beta | |
| DE60319135D1 (de) | Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden | |
| ATE335496T1 (de) | Angiotensin ii und analoga zur begrenzung von narben und adhäsionbildung | |
| DE60323973D1 (de) | Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd | |
| DE60239864D1 (de) | Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen | |
| BR0206844A (pt) | Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos | |
| DE50214008D1 (de) | Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein | |
| DE602004016547D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| MXPA04011018A (es) | Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias. | |
| EA200901145A1 (ru) | Применение рибофлавина в лечении гипертензии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1497330 Country of ref document: EP |